ALGOS: the development of a randomized controlled trial testing a case management algorithm designed to reduce suicide risk among suicide attempters

<p>Abstract</p> <p>Background</p> <p>Suicide attempts (SA) constitute a serious clinical problem. People who attempt suicide are at high risk of further repetition. However, no interventions have been shown to be effective in reducing repetition in this group of patients.</p> <p>Methods/Design</p> <p>Multicentre randomized controlled trial.</p> <p>We examine the effectiveness of «ALGOS algorithm»: an intervention based in a decisional tree of contact type which aims at reducing the incidence of repeated suicide attempt during 6 months. This algorithm of case management comprises the two strategies of intervention that showed a significant reduction in the number of SA repeaters: systematic telephone contact (ineffective in first-attempters) and «Crisis card» (effective only in first-attempters). Participants who are lost from contact and those refusing healthcare, can then benefit from «short letters» or «postcards».</p> <p>Discussion</p> <p>ALGOS algorithm is easily reproducible and inexpensive intervention that will supply the guidelines for assessment and management of a population sometimes in difficulties with healthcare compliance. Furthermore, it will target some of these subgroups of patients by providing specific interventions for optimizing the benefits of case management strategy.</p> <p>Trial Registration</p> <p>The study was registered with the ClinicalTrials.gov Registry; number: NCT01123174.</p

Beef and Lamb carcass grading to underpin consumer satisfaction

Le « Meat Livestock Australia » et l’INRA ont organisé un congrès international sur la prédiction de la qualité sensorielle de la viande bovine et ovine pour le consommateur. Durant deux jours, 19 présentations ont souligné que, de nos jours, la viande de ruminant doit répondre aux attentes gustatives des consommateurs qui achètent de la viande rouge pour leurs repas. L'accent a été mis sur le système de prédiction de la qualité MSA (pour Meat Standards Australia) qui a été conçu comme un système de prévision de la qualité sensorielle pour les viandes cuites à consommer dans diverses occasions sans pour autant nécessiter de connaissances spécifiques de la part des consommateurs. Ce congrès a reconnu unanimement la nécessité d’un tel système de prédiction de la qualité des viandes bovines et ovines afin de fidéliser les acheteurs parfois tentés de consommer des viandes blanches moins chères. Les 80 participants au congrès de 17 pays (Australie, Brésil, Canada, Chine, République tchèque, Danemark, France, Italie, Japon, Irlande, Pologne, Portugal, Afrique du Sud, Espagne, Thaïlande, Royaume-Uni, USA) ont travaillé de façon dynamique et collective. En effet, il a été décidé de créer un groupe de travail international avec les pays actuellement impliqués tout en étant ouvert à de nouveaux partenaires afin de mettre en oeuvre les recommandations issues du congrès

Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia

Background: Chronic lymphocytic leukemia (CLL) cells are often affected by genomic aberrations targeting key regulatory genes. Although fludarabine is the standard first line therapy to treat CLL, only few data are available about the resistance of B cells to this purine nucleoside analog in vivo. Here we sought to increase our understanding of fludarabine action and describe the mechanisms leading to resistance in vivo. We performed an analysis of genomic aberrations, gene expression profiles, and microRNAs expression in CLL blood B lymphocytes isolated during the course of patients' treatment with fludarabine. Results: In sensitive patients, the differentially expressed genes we identified were mainly involved in p53 signaling, DNA damage response, cell cycle and cell death. In resistant patients, uncommon genomic abnormalities were observed and the resistance toward fludarabine could be characterized based on the expression profiles of genes implicated in lymphocyte proliferation, DNA repair, and cell growth and survival. Of particular interest in some patients was the amplification of MYC (8q) observed both at the gene and transcript levels, together with alterations of myc-transcriptional targets, including genes and miRNAs involved in the regulation of cell cycle and proliferation. Differential expression of the sulfatase SULF2 and of miR-29a, -181a, and -221 was also observed between resistant and sensitive patients before treatment. These observations were further confirmed on a validation cohort of CLL patients treated with fludarabine in vitro. Conclusion: In the present study we identified genes and miRNAs that may predict clinical resistance of CLL to fludarabine, and describe an interesting oncogenic mechanism in CLL patients resistant to fludarabine by which the complete MYC-specific regulatory network was altered (DNA and RNA levels, and transcriptional targets). These results should prove useful for understanding and overcoming refractoriness to fludarabine and also for predicting the clinical outcome of CLL patients before or early during their treatment

TULIPP: Towards Ubiquitous Low-power Image Processing Platforms

Many industrial domains rely on vision-based applications which require to comply with severe performance and embedded requirements. TULIPP will develop a reference platform, which consists of a hardware system, a tool chain and a real-time operating system. This platform defines implementation rules and interfaces to tackle power consumption issues while delivering high, energy efficient and guaranteed computing performance for image processing applications. Using this reference platform will enable designers to develop a complete solution at a reduced cost to meet the typical embedded systems requirements: Size, Weight and Power. Moreover, for less constrained systems which performance requirements cannot be fulfilled by one instance of the platform, the reference platform will also be scalable so that the resulting boards can be chained for higher processing power. The instance of the reference platform developed during the project will be use-case driven and split between the implementation of: a reference hardware architecture - a scalable low-power board; a low-power operating system and image processing libraries; a productivityenhancing tool chain. It will lead to three proof-of-concept demonstrators across different application domains: real-time and low-power medical image processing product prototype of surgical X-ray system (mobile c-arm); embedded image processing systems within Unmanned Aerial Vehicles (UAVs); automotive real time embedded systems for driver assistance. TULIPP will set up an ecosystem and will closely work with standardization organizations to propose new standards derived from its reference platform to the industry.© 2016 IEEE. Personal use of this material is permitted. Permission from IEEE must be obtained for all other uses, in any current or future media, including reprinting/republishing this material for advertising or promotional purposes, creating new collective works, for resale or redistribution to servers or lists, or reuse of any copyrighted component of this work in other works.

BrainStorm: A brain metastases research platform to tackle the challenge of central nervous system (CNS) metastases in solid tumors (Oncodistinct 006).

International audienceTPS2066 Background: Better knowledge on the evolving epidemiology and biology of CNS metastases are key elements for the development of new treatment strategies and identification of promising therapeutic targets. A multidisciplinary Brain Metastases Clinical Research Platform called BrainStorm was launched by the Jules Bordet Institute and the Oncodistinct network. The BrainStorm program includes mainly patients with non-CNS metastatic solid tumors with high risk of developing CNS metastases allowing to build a large database focusing on three time periods: before the diagnosis of CNS metastases (Part A), at diagnosis (Part B) and after the diagnosis of CNS metastases (Part C). Methods: Subjects with newly diagnosed non-CNS metastases or up to 24 months from diagnosis of non-CNS metastases from triple-negative and HER2-positive breast cancer, lung cancer and melanoma are eligible for part A of the program. Subjects presenting with a 1st CNS event and not yet enrolled (previously mentioned cohorts and a cohort of other tumor types) can enter directly in parts B and subsequently part C of the study. Eligible subjects are followed for 48 months for relevant clinical data, neurological examinations, quality of life, survival status, and undergo examinations and samplings (Table 1). A total of 280 subjects (40 per cohort) with a 1st CNS event will be enrolled. The main objectives of the program are to collect clinical and biological data with the aim to identify risk factors for CNS metastases development (Part A) and to better understand the biology of CNS metastases (brain and leptomeningeal –Parts B and C) aiming to discover new targets for therapy and intensify the multidisciplinary approach for the management of CNS metastases from solid tumors. The translational part of the program will evaluate among others the use of cerebrospinal fluid circulating tumor DNA (CSF-ctDNA) as a surrogate for CNS metastases in order to characterize its molecular landscape. Currently, the study is recruiting in several sites within the Oncodistinct network. The data collected will help to develop innovative multidisciplinary research projects that could be implemented in all parts of the BrainStorm program. Clinical trial information: NCT04109131. [Table: see text

Reprise de la discussion sur les évènements de la veille aux Jacobins, lors de la séance du 20 brumaire an III (10 novembre 1794)

Legendre (de Paris) Louis, Camboulas Simon, Clauzel Jean-Baptiste, Le Tourneur Etienne-Francois-Louis-Honnoré, Thierriet Claude, Duhem Pierre-Joseph, Lesage-Senault Gaspard-Jean-Joseph, Prieur (de la Marne), Billaud-varenne Jacques nicolas, Pérès de Lagesse Emmanuel, Baudin Pierre charles louis, Du Roy Jean-Michel, Goupilleau (de Fontenay) Jean-François. Reprise de la discussion sur les évènements de la veille aux Jacobins, lors de la séance du 20 brumaire an III (10 novembre 1794). In: Archives Parlementaires de 1787 à 1860 - Première série (1787-1799) Tome CI - Du 19 au 30 brumaire an III (9 au 20 novembre 1794) Paris : CNRS éditions, 2005. pp. 80-83